DIAGNOS Inc. (DGNOF)
OTCMKTS · Delayed Price · Currency is USD
0.1480
-0.0043 (-2.80%)
Jul 25, 2025, 3:32 PM EDT
DIAGNOS Revenue
In the fiscal year ending March 31, 2025, DIAGNOS had annual revenue of 103.80K CAD, down -39.00%. DIAGNOS had revenue of 18.39K in the quarter ending March 31, 2025, a decrease of -56.21%.
Revenue
103.80K CAD
Revenue Growth
-39.00%
P/S Ratio
211.04
Revenue / Employee
4.72K CAD
Employees
22
Market Cap
15.24M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 103.80K | -66.36K | -39.00% |
Mar 31, 2024 | 170.16K | -315.59K | -64.97% |
Mar 31, 2023 | 485.75K | 46.92K | 10.69% |
Mar 31, 2022 | 438.83K | 171.76K | 64.31% |
Mar 31, 2021 | 267.07K | -64.44K | -19.44% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
DIAGNOS News
- 6 weeks ago - DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States - GlobeNewsWire
- 7 weeks ago - DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market - GlobeNewsWire
- 2 months ago - DIAGNOS Announces the Engagement of Allele Capital Partners - GlobeNewsWire
- 2 months ago - DIAGNOS Announces Amendment to Convertible Debentures - GlobeNewsWire
- 3 months ago - DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application - GlobeNewsWire
- 3 months ago - DIAGNOS Provides Additional Information on Amendment to Convertible Debentures - GlobeNewsWire
- 3 months ago - DIAGNOS Provides Update on its Health Canada Medical Device Licence Application - GlobeNewsWire
- 4 months ago - DIAGNOS amends terms of convertible debentures - Seeking Alpha